Zydus to acquire 2 biologics manufacturing units in U.S. from Agenus for $125 million
Zydus Lifesciences plans to acquire Nasdaq-listed clinical-stage immuno-oncology firm Agenus's two biologics manufacturing facilities in California, U.S. for $125 million to enter the global biologics contract development and manufacturing organization (CDMO) business.
The move enables it to leverage supply chain dynamics and a favourable geopolitical environment to expand reach in the U.S. and globally.
The facilities in Emeryville and Berkeley will be acquired for an upfront consideration of $75 million and contingent payment of $50 million, to be paid over three years subject to achievement of certain revenue milestone. Zydus said the acquisition, through a subsidiary, will provide access to advanced biologics manufacturing capabilities and establish a key presence in the leading global biotechnology hub of California.
Also as a part of the transaction Zydus will become an exclusive contract manufacturer for Agenus and provide manufacturing services for clinical and commercial supply of two identified Phase-3 ready immuno-oncology products, Botensilimab (BOT) and Balstilimab (BAL).
Zydus will also have first right of negotiation to manufacture any of the future pipeline products developed by Agenus.
Create jobs, spur local economy
With the acquisition Zydus will become a one stop solution provider across the entire development spectrum of biologics, from pre-clinical to toxicology studies, clinical development to manufacturing. Zydus said it intends to further expand the team and help create new jobs in the region and contribute to the local economy.
Zydus' CDMO business will operate as an independent entity and will house the acquired manufacturing capabilities. 'The acquisition will give Zydus a strategic foothold in the U.S. for biologics manufacturing in the global hub for biotech innovation, California. It will enhance our ability to partner with innovation-centric entities, advancing new products and prioritizing patient-centric solutions,' MD Sharvil Patel said.
In a parallel development, Zydus Lifesciences has entered into a definitive agreement with Agenus Inc. to secure exclusive commercial rights for India and Sri Lanka for BOT and BAL.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
US stocks slide lower as investors focus on trade, key jobs data
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Wall Street remains listless on Thursday, as the countdown ticks toward Friday's highly anticipated jobs S&P 500 was 0.3% lower in morning trading. After sprinting through May and rallying within a couple good days' worth of gains of its all-time high, the index at the center of many 401(k) accounts has lost momentum as financial markets wait for the next big trigger to move, up or Dow Jones Industrial Average was down 162 points, or 0.4%, as of 10 a.m. Eastern time, and the Nasdaq composite was 0.2% activity in options markets suggests investors believe the next big move for the S&P 500 could come on Friday, when the U.S. Labor Department will say how many more jobs U.S. employers created than destroyed during May. The expectation on Wall Street is for a slowdown in hiring from April.A resilient job market has been one of the linchpins that's propped up the U.S. economy, and the worry is that all the uncertainty created by President Donald Trump's on-and-off tariffs could cause businesses to freeze their & Gamble, the giant behind such brands as Pampers diapers and Cascade dish detergent, said Thursday it will cut up to 7,000 jobs over the next two years to boost its ability to make profit. Its stock fell 1.7%.A report on Thursday said that more U.S. workers applied for unemployment benefits last week than economists expected. The number still remains relatively low compared with history, but it hit its highest level in eight months.A separate report said that U.S. workers overall produced less stuff per hour during the start of the year than economists expected. The drop in productivity is a potentially discouraging trend for Wall Street, Five Below rallied 10.7% after the retailer, which sells products priced between $1 and $5, reported a stronger profit for the latest quarter than analysts expected. CEO Winnie Park credited broad-based strength across most of its jumped 17.4% after the database company likewise delivered a stronger profit than analysts the losing side of Wall Street was Brown-Forman, the company behind Jack Daniel's and Woodford Reserve. Its profit and revenue for the latest quarter fell short of Wall Street's expectations, and the company said it expects its upcoming fiscal year to be challenging because of 'consumer uncertainty, the potential impact from currently unknown tariffs' and other things. Its stock fell 15.6%.The CEO of PVH, the company behind the Calvin Klein and Tommy Hilfiger brands, likewise cited challenges from 'an increasingly uncertain consumer and macroeconomic backdrop.'Its stock fell 18.4% even though it reported stronger revenue and profit for the latest quarter than analysts expected. The company cut its profit forecast for its full fiscal year, saying it will likely be able to offset only some of the potential hit it will take because of that Trump would lower his tariffs after reaching trade deals with other countries have been among the main reasons the S&P 500 has rallied back after dropping roughly 20% below its record two months ago. But talks are still ongoing, and nothing is assured. In the meantime, many companies have been cutting or withdrawing their forecasts for profit this upcoming year because of all the spoke with China's leader, Xi Jinping, on Thursday amid hopes for progress between the world's two largest economies. The conversation was confirmed by the Chinese foreign ministry, which said Trump initiated the call. The White House did not immediately are also building that the Federal Reserve will need to cut interest rates later this year in order to prop up the economy. Yields took a sharp turn lower on Wednesday after reports came in weaker than expected on the U.S. job market and on activity among U.S. services Fed has yet to cut interest rates this year after slashing them through the end of 2024. Part of the reason for the pause is that the Fed wants to see how much Trump's tariffs will hurt the economy and raise inflation. While lower interest rates could boost the economy, they also tend to give inflation more yields held steadier on Thursday ahead of Friday's jobs report. The yield on the 10-year Treasury eased to 4.35% from 4.37% late Wednesday after tumbling from 4.46% the day stock markets abroad, indexes were mixed amid modest moves across much of Europe after the European Central Bank cut its main interest rate again, as was widely moves were larger in Asia, where South Korea's Kospi jumped 1.5% after the country's new president and leading liberal politician Lee Jae-myung began his term, vowing to restart talks with North Korea and beef up a partnership with the U.S. and Japan.
Time of India
4 hours ago
- Time of India
US markets hold steady: Wall Street edges up ahead of US jobs data; Fed rate cut bets rise amid hiring concerns
US stocks traded slightly higher Thursday as investors awaited key employment data, while fresh signals of labour market softness stoked expectations of a rate cut later this year. Tired of too many ads? go ad free now The S&P 500 rose 0.2% in early trading, while the Dow Jones Industrial Average was up 48 points, or 0.1%. The Nasdaq composite also gained 0.2%. Investors are focused on the US Labour Department's monthly jobs report due Friday, which is expected to show that employers added 130,000 jobs in May — down from 177,000 in April. According to the Associated Press, markets were responding to early signs of weakening momentum in the labour market, along with uncertainty tied to President Donald Trump's on-and-off tariff policy. Analysts say concerns over hiring slowdowns may prompt the Federal Reserve to cut interest rates later this year. Earlier this week, a report by payroll provider ADP showed that private employers added fewer jobs than expected, contributing to pressure on the Fed to act. On Thursday, the government was also set to release its weekly jobless claims report, a key indicator of layoffs. The Fed has held off on cutting rates so far this year after multiple reductions through 2024. Policymakers are monitoring the inflationary impact of Trump's tariffs alongside broader economic risks. Trump recently urged Fed Chair Jerome Powell to move faster on rate cuts following the ADP data miss. In corporate news, Procter & Gamble shares were flat after confirming a plan to cut 7,000 non-manufacturing jobs — about 15% of its workforce — over two years as part of a restructuring strategy. Among other movers, teen discount retailer Five Below surged 6.5% after beating analyst forecasts on both revenue and profit and raising its full-year guidance. Tired of too many ads? go ad free now PVH Corp., the parent of Calvin Klein and Tommy Hilfiger, fell nearly 8% after it slashed its full-year profit outlook, citing tariff-related pressures. In global markets, France's CAC 40 and Germany's DAX each rose 0.3%, while the UK's FTSE 100 gained 0.2%. In Asia, Japan's Nikkei 225 dropped 0.5%, while South Korea's Kospi jumped 1.5% after newly elected President Lee Jae-myung pledged to restart North Korea dialogue and strengthen ties with the US and Japan. Hong Kong's Hang Seng gained 1.1%, the Shanghai Composite rose 0.21%, and Australia's S&P/ASX 200 was flat. In commodities, US crude added 15 cents to $63 a barrel, while Brent crude gained 20 cents to $65.06 a barrel. In currency trade, the dollar climbed to 143.19 Japanese yen from 142.78. The euro was slightly higher at $1.1425, up from $1.1418.
&w=3840&q=100)
Business Standard
4 hours ago
- Business Standard
Dr Reddy's, Alvotech to co-develop biosimilar of cancer drug Keytruda
Global biotech major Alvotech and Hyderabad-based Dr Reddy's Laboratories (DRL) have entered into a collaboration to co-develop, manufacture, and commercialise a biosimilar version of Merck's blockbuster cancer drug Keytruda (pembrolizumab), which recorded global sales of $29.5 billion in 2024. Shares of DRL rose 3 per cent on Thursday on the BSE following the announcement. Under the agreement, both parties will jointly manage development and manufacturing responsibilities, while sharing associated costs. Each company will also hold global commercialisation rights, subject to certain exceptions. Keytruda, developed by Merck & Co., is used to treat a wide range of cancers, including lung, melanoma, and head and neck cancers. With patents for Keytruda expected to expire in major markets over the next few years, competition among biosimilar developers is intensifying. The partnership is a strategic boost to Dr Reddy's oncology portfolio—a key therapeutic area for the company—and significantly expands Iceland-based Alvotech's biosimilar pipeline. The tie-up comes amid growing global demand for cost-effective biologic alternatives in cancer care, especially in immuno-oncology, where Keytruda remains a dominant therapy. 'We are happy to collaborate with Alvotech for the pembrolizumab biosimilar,' said Erez Israeli, CEO of Dr Reddy's. 'Oncology has been a top focus therapy area for us, and this collaboration further enhances our capabilities.' Alvotech Chairman and CEO Róbert Wessman said the partnership would accelerate development while broadening global access to critical biologics. 'This agreement demonstrates our ability to leverage our R&D and manufacturing platform to pursue growing global markets,' he said. Alvotech, listed on Nasdaq, is focused solely on biosimilars and already has approvals for adalimumab and ustekinumab biosimilars. Its pipeline includes candidates for autoimmune, respiratory, and oncologic indications. Dr Reddy's, which has commercialised six biosimilars in India and over 30 countries, has been scaling up global biologics operations. It launched its first biosimilar in the UK—Versavo (bevacizumab)—in 2024, and pegfilgrastim in the US and Europe through partners. With this collaboration, both companies aim to play a larger role in shaping the next phase of affordable cancer care globally.
